NCT05781360View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

May 25, 2024

Study Completion Date

May 25, 2024

Conditions
Locally Advanced Unresectable or Metastatic Solid Tumor
Interventions
DRUG

SIM0237

SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens

Trial Locations (9)

10016

NYU Langone, New York

46202

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

77030

University of Texas MD Anderson Cancer Center, Houston

230061

Anhui Provincial Hospital, Hefei

250117

Shandong Cancer Hospital, Jinan

310003

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

350014

Fujian Cancer Hospital, Fuzhou

410031

Hunan Cancer Hospital, Changsha

450003

Henan Cancer Hospital, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

Shanghai Xianxiang Medical Technology Co., Ltd.

INDUSTRY

collaborator

Simcere Zaiming

UNKNOWN

lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY